Day: March 1, 2022

ER-Kim Gains Exclusive Rights to Commercialize QRX003 to Six Additional Countries 60 Countries Now Covered by Partnership Agreements for QRX003ASHBURN, Va., March 01, 2022 (GLOBE NEWSWIRE) — Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a specialty pharmaceutical company focused on rare and orphan diseases, today announced that its wholly-owned subsidiary, Quoin Pharmaceuticals, Inc., has extended its exclusive Distribution Agreement with ER-Kim, a partner for biotech companies in Central and Eastern Europe (“CCE”), for QRX003, the Company’s investigational treatment for Netherton Syndrome, a rare and devastating genetic disease for which there is currently no available treatment or cure. Under the terms of the revenue sharing agreement, which was initially announced earlier in February 2022, ER-Kim...

YAVNE, Israel, March 01, 2022 (GLOBE NEWSWIRE) — MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced that management would present at two upcoming investor conferences in March. Details for each is a follows:Cowen’s 42nd Annual Health Care ConferenceDate: Wednesday, March 9, 2022Time: 9:10 am ETLink: Click here   OppenheimerDate: March 17, 2022Time: 11:20 am ETLink: Click hereA replay of the fireside chat and presentation will be available on the Events page of the MediWound Investor Relations website at https://ir.mediwound.com/events-and-presentations. About MediWound Ltd.MediWound is a biopharmaceutical company that develops, manufactures, and commercializes novel, cost...

SAN FRANCISCO, March 01, 2022 (GLOBE NEWSWIRE) — Augmedix, Inc. (Nasdaq: AUGX), a leading provider of automated medical documentation and data services, today announced the company will be presenting in the upcoming JMP Securities Technology Conference in San Francisco. Manny Krakaris, Chief Executive Officer of Augmedix, will be presenting on Tuesday, March 8, 2022, at 11:30 a.m. Pacific Time. Interested parties may access a live and archived webcast of the presentation on the “Investor Relations” section of the company’s website at: https://ir.augmedix.com/news-events/ir-calendar. About Augmedix Augmedix, Inc. (Nasdaq: AUGX) provides automated medical documentation and data services to large healthcare systems and physician practices, supporting medical offices, clinics, hospitals, emergency departments, and telemedicine nationwide....

On schedule to run a full pilot on Li and other high-value battery minerals in 2022Lithium Hydroxide Lithium Hydroxide produced at the Aqua Metals Innovation Center in Tahoe Reno Industrial Center, NV.Lithium Hydroxide and Black Mass The Lithium hydroxide was produced from black mass made up of a mix of lithium-ion batteries. Li AquaRefining will be able to process black mass made from any mix of lithium-ion batteries.RENO, Nev., March 01, 2022 (GLOBE NEWSWIRE) — Aqua Metals, Inc. (NASDAQ: AQMS) (“Aqua Metals” or the “Company”), a leading innovator in metals recycling with its AquaRefining™ technology, has achieved a key milestone and potentially an important industry breakthrough by producing its first lithium hydroxide from lithium-ion battery black mass at the Company’s Innovation Center in the...

SOUTH SAN FRANCISCO, Calif., March 01, 2022 (GLOBE NEWSWIRE) — UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that members of its senior management team will provide a corporate update and participate in one-on-one investor meetings at the Cowen 42nd Annual Health Care Conference taking place virtually on Monday, March 7, 2022, at 11:10 a.m. ET. The presentation will be available through the Cowen conference portal and will also be available through the Investors & Media section of UNITY’s website. An archived replay will be available for 90 days following the event. About UNITY UNITY is developing a new class of therapeutics to slow, halt, or reverse diseases of aging. UNITY’s current focus is on creating medicines...

IRVINE, Calif., March 01, 2022 (GLOBE NEWSWIRE) — Inari Medical, Inc. (NASDAQ: NARI) (“Inari”) a medical device company with a mission to treat and transform the lives of patients suffering from venous and other diseases, today announced the appointment of Mr. Robert Warner to its board of directors. Mr. Warner will serve as a member of the Audit Committee of the board. “We are pleased to welcome Robert as a new independent director to our board. Mr. Warner’s decades of executive operating experience, including internationally, will be highly valuable to Inari as we enter the next phase of our mission to treat and transform the lives of patients suffering from venous and other diseases,” said Bill Hoffman, Inari’s Chief Executive Officer. From August 2015 to February 2018, Mr. Warner served as President and General Manager of Alcon...

Evolution Credit Limited up to SEK 260,000,000 and up to NOK 135,000,000 Senior Unsecured Callable Bonds 2013/2028 ISIN: SE 000 5392560 and NO 001 0689342 (the “Bonds”) Johannesburg, 1 March 2022 Reference is made to the terms and conditions for the Bonds, originally dated 16 September 2013, as amended and restated, most recently by an amendment and restatement agreement dated 22 September 2020 (the “Terms and Conditions“). Partial repayment In addition to scheduled amortizations, the Company is obliged to apply excess cash to repay Senior Unsecured Loans. If repayments are made under Senior Unsecured Loans, corresponding pro rata payments shall be made under the Bonds. The Company will therefore make an increased early partial redemption of the Bonds pursuant to Clauses 9.6 (Mandatory redemption pro rata in case...

VANCOUVER, British Columbia, March 01, 2022 (GLOBE NEWSWIRE) — Patriot Battery Metals Inc. (the “Company” or “Patriot”) (CSE: PMET) (OTCQB: PMETF) (FSE: R9GA) is pleased to announce it has mobilized the first of two drill rigs to commence the winter drill program at its wholly owned Corvette Lithium Property (the “Property”), located in the James Bay Region of Quebec. The target drill area at the CV Lithium Trend is located approximately 13.5 km south of the regional and all-weather Trans-Taiga Road and powerline infrastructure. The winter phase of the planned 15,000 to 20,000 m drill exploration campaign will focus on further delineation of the CV1 through CV7 lithium pegmatite outcrop corridor, where the initial four (4) drill holes to test the CV5-6 Prospect returned strong lithium-tantalum mineralization. This is highlighted...

– Oppenheimer 32nd Annual Healthcare Conference – – AD/PD™ 2022 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological Disorders – – Krabbe Translational Research Network Meeting – BETHESDA, Md., March 01, 2022 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”), a biotechnology company focused on identifying and optimizing allosteric binding sites that have never been targeted in neurodegenerative diseases and lysosomal storage disorders, today announced that it will be participating in upcoming investor and scientific conferences. Eric Richman, Chief Executive Officer of Gain Therapeutics, will present at the Oppenheimer 32nd Annual Healthcare Conference and invites investors to participate via webcast and in one-on-one meetings. The company...

BASKING RIDGE, N.J., March 01, 2022 (GLOBE NEWSWIRE) — Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of innovative therapies designed to treat or reverse disease, today announced that it has received $2.3 million in non-dilutive funding as an approved participant of the Technology Business Tax Certificate Transfer Program (the “Program”) sponsored by the New Jersey Economic Development Authority (“NJEDA”). The Program enables qualifying New Jersey-based biotechnology or technology companies to sell a percentage of their New Jersey net operating losses (“NOLs”) and research and development tax credits to unrelated qualifying corporations. “We appreciate the NJEDA’s continued support of the New Jersey biotech community under this...